Table 1 Tumor collection and BC subtypes.

From: ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer

 

All BC cases

Non-lobular BC

Lobular BC

   
 

n

(%)

n

(%)

n

(%)

P-value

Test

Notes

All cases

622

(100.0)

443

(100.0)

179

(100.0)

   

Age at diagnosis

   Median (range) in yrs

54

(28-76)

54

(28-76)

57

(28-75)

   

pT stage

   pT1

371

(59.6)

274

(61.8)

97

(54.2)

0.0712

FET

pT1 vs pT2+

   pT2

223

(35.9)

154

(34.8)

69

(38.5)

0.0247

FET

pT1/2 vs pT3+

   pT3

24

(3.9)

12

(2.7)

12

(6.7)

   

   pT4

2

(0.3)

1

(0.2)

1

(0.6)

   

   n.a.

2

(0.3)

2

(0.5)

0

(0.0)

   

pN stage

   pN0

541

(87.0)

379

(85.5)

162

(90.5)

0.1439

FET

pN0 vs pN1+

   pN1+

79

(12.7)

62

(14.0)

17

(9.5)

   

   n.a.

2

(0.3)

2

(0.5)

0

(0.0)

   

Histological grade, baseline

   G1

46

(7.4)

33

(7.4)

13

(7.3)

0.0017

FET

G1/2 vs G3

   G2

399

(64.1)

268

(60.5)

131

(73.2)

   

   G3

177

(28.5)

142

(32.1)

35

(19.5)

   

   n.a.

0

(0.0)

0

(0.0)

0

(0.0)

   

ER status, baseline

   Negative

1

(0.2)

1

(0.2)

0

(0.0)

1.0000

FET

ER pos vs neg

   Low expressiona

0

(0.0)

0

(0.0)

0

(0.0)

   

   Positive

620

(99.6)

442

(99.8)

178

(99.4)

   

   n.a.

1

(0.2)

0

(0.0)

1

(0.6)

   

ER status, post-pET

   Negative

0

(0.0)

0

(0.0)

0

(0.0)

-

FET

ER pos vs neg

   Low expressiona

1

(0.2)

0

(0.0)

1

(0.6)

   

   Positive

620

(99.6)

442

(99.8)

178

(99.4)

   

   n.a.

1

(0.2)

1

(0.2)

0

(0.0)

   

PR status, baseline

   Negative

46

(7.4)

32

(7.2)

14

(7.8)

0.8657

FET

PR pos vs neg

   Low expressiona

27

(4.3)

22

(5.0)

5

(2.8)

   

   Positive

549

(88.3)

389

(87.8)

160

(89.4)

   

   n.a.

0

(0.0)

0

(0.0)

0

(0.0)

   

PR status, post-pET

   Negative

137

(22.0)

99

(22.4)

38

(21.2)

0.8310

FET

PR pos vs neg

   Low expressiona

65

(10.5)

48

(10.8)

17

(9.5)

   

   Positive

420

(67.5)

296

(66.8)

124

(69.3)

   

   n.a.

0

(0.0)

0

(0.0)

0

(0.0)

   

HER2 status, baseline (According to ASCO/CAP guidelines)

   Negative

615

(98.9)

437

(98.7)

178

(99.4)

0.3285

FET

HER2 pos vs neg

   Positive

5

(0.8)

5

(1.1)

0

(0.0)

   

   n.a.

2

(0.3)

1

(0.2)

1

(0.6)

   

HER2 status, post-pET (According to ASCO/CAP guidelines)

   Negative

613

(98.5)

435

(98.2)

178

(99.4)

0.4495

FET

HER2 pos vs neg

   Positive

8

(1.3)

7

(1.6)

1

(0.6)

   

   n.a.

1

(0.2)

1

(0.2)

0

(0.0)

   

Ki67, baseline

   0–9

72

(11.6)

42

(9.5)

30

(16.8)

0.0127

FET

Ki67 <10 vs ≥10

   10–19

244

(39.2)

163

(36.8)

81

(45.2)

   

   20–34

222

(35.7)

171

(38.6)

51

(28.5)

   

   35–100

84

(13.5)

67

(15.1)

17

(9.5)

   

   n.a.

0

(0.0)

0

(0.0)

0

(0.0)

   

Ki67, post-pET

   0–9

327

(52.6)

223

(50.4)

104

(58.1)

0.0919

FET

Ki67 <10 vs ≥10

   10–19

186

(29.9)

134

(30.2)

52

(29.0)

   

   20–34

87

(14.0)

67

(15.1)

20

(11.2)

   

   35–100

22

(3.5)

19

(4.3)

3

(1.7)

   

   n.a.

0

(0.0)

0

(0.0)

0

(0.0)

   

Ki67, dynamic categories (according to the POETIC trial18)

   Low–low

59

(9.5)

38

(8.6)

21

(11.7)

0.0169

CSTT

 

   High–low

268

(43.1)

185

(41.8)

83

(46.4)

0.0235

FET

high/high vs x/low

   High–high

282

(45.3)

216

(48.7)

66

(36.9)

   

   Low–highb

13

(2.1)

4

(0.9)

9

(5.0)

   

   n.a.

0

(0.0)

0

(0.0)

0

(0.0)

   

E-cadherin, baseline

   Negative

171

(27.5)

11

(2.5)

160

(89.4)

<0.0001

FET

E-cad pos vs neg

   Positive

411

(66.1)

402

(90.7)

9

(5.0)

   

   n.a.

40

(6.4)

30

(6.8)

10

(5.6)

   

E-cadherin, post-pET

   Negative

169

(27.2)

9

(2.0)

160

(89.4)

<0.0001

FET

E-cad pos vs neg

   Positive

418

(67.2)

408

(92.1)

10

(5.6)

   

   n.a.

35

(5.6)

26

(5.9)

9

(5.0)

   

Oncotype DX RS, baseline

   0–11

142

(22.8)

101

(22.8)

41

(22.9)

0.0002

FET

RS 0-25 vs 26-100

   12–25

362

(58.2)

241

(54.4)

121

(67.6)

   

   26–100

101

(16.3)

87

(19.6)

14

(7.8)

   

   n.a.

17

(2.7)

14

(3.2)

3

(1.7)

   

pET agent

   Tamoxifen

286

(46.0)

204

(46.0)

82

(45.8)

0.9294

FET

TAM vs AI

   Aromatase inhibitors

334

(53.7)

237

(53.5)

97

(54.2)

   

   n.a.

2

(0.3)

2

(0.5)

0

(0.0)

   
  1. Unless otherwise stated, the values are given in the format n (%), with n corresponding to the number of patients. The Fisher’s exact test (FET) and Chi-Square test for trends (CSTT) were used for statistical analysis. Significant differences are highlighted in bold.
  2. n.a. not available, ER estrogen receptor, PR progesterone receptor, pET preoperative endocrine therapy, RS recurrence score, TAM tamoxifen, AI aromatase inhibitors.
  3. aLow expression (ER and PR status) was defined as 1–9% positive cells.
  4. bPatients classified into low-high group were excluded for statistical analysis.
Back to article page